OncoMatch/Clinical Trials/NCT07167329
Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial
Is NCT07167329 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Belzutifan for von hippel lindau.
Treatment: Belzutifan — The BELIEVE-VHL Trial is a prospective real-life study designed to evaluate the therapeutic effects, benefits, and adverse effects of belzutifan, as well as the timing of treatment response and disease progression in patients with von Hippel-Lindau (VHL) syndrome.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Biomarker criteria
Required: VHL pathogenic mutation or clinical diagnosis
Clinical or genetic confirmation of von Hippel-Lindau (VHL) syndrome
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Radiotherapy administered within 4 weeks prior to study enrollment
Cannot have received: surgery
Major surgical procedure, including for VHL-related tumors, within 4 weeks prior to study enrollment, or immediate need for surgical intervention for tumor management
Lab requirements
Blood counts
adequate bone marrow function as defined by laboratory reference values
Kidney function
adequate renal function as defined by laboratory reference values
Liver function
adequate hepatic function as defined by laboratory reference values
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify